InvestorsObserver
Sign Up Login

OMER Omeros Corp

$6.74 $0.00 (0.00%)
Add to Watchlist Compare
Overall

OMER Stock Analysis Overview

What this means: Omeros Corp (OMER) gets an Overall Rank of 71, which is an above average rank under InvestorsObserver's stock ranking system. Our system considers the available information about the company and then compares it to all the other stocks we have data on to get a percentile-ranked value. OMER's 71 means that it ranks higher than 71% of stocks.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

View Sample Report
Fundamental PREMIUM

OMER Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

Short-Term Technical PREMIUM

OMER Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

Long-Term Technical PREMIUM

OMER Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

Analyst Ranking PREMIUM

OMER Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

Valuation PREMIUM

OMER Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

Stock Sentiment PREMIUM

OMER Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

OMER Stock Analysis Overview

What this means: Omeros Corp (OMER) gets an Overall Rank of 71, which is an above average rank under InvestorsObserver's stock ranking system. Our system considers the available information about the company and then compares it to all the other stocks we have data on to get a percentile-ranked value. OMER's 71 means that it ranks higher than 71% of stocks.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

Create a FREE account to see full OMER report

OMER Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

OMER Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

OMER Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

OMER Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

OMER Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

OMER Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

Omeros Corp (OMER) Analyst Forecast

OMER Price, Volume, Earnings, and Dividend Date

  • Last Price $6.74
  • Previous Close $6.74
  • Change $0.00
  • Open $6.92
  • Volume 563,600
  • Avg. Volume (100-day) 1,186,782
  • Market Cap 422,800,301
  • Days Range 6.66 - 6.9566
  • 52-week Range 1.86 - 16.57
  • Dividend Yield —
  • Ex. Dividend Date —
  • P-E 2.3
  • EPS 3.13000011
  • Earnings Date 11/07/22
  • Sector Healthcare
  • Industry Biotechnology
  • Avg. Analyst Rec. Premium
  • Beta 2.367
  • PEG Ratio —

Omeros Corp (OMER) Company Description

Omeros Corp is a United States-based biopharmaceutical company. Its goal is to research, develop, and commercialize small-molecule and protein therapeutics targeting inflammation, coagulopathies, and disorders of the central nervous system. The company owns Omidria (phenylephrine and ketorolac injection), approved by the U.S. Food and Drug Administration and launched in the U.S. for use during cataract surgery and intraocular lens replacement. Its product pipeline is focused on complement-associated thrombotic microangiopathies; complement-mediated glomerulonephropathies; Huntington's disease and cognitive impairment; and addictive and compulsive disorders.

Omeros Corp (OMER) Stock Chart

View Interactive OMER chart

My Watchlists

Follow Your Favorite Stocks

Top Stocks in Biotechnology

Company Price
Arcutis Biotherapeutics Inc (ARQT) (ARQT) $24.72
Trevi Therapeutics Inc (TRVI) (TRVI) $3.78
Savara Inc (SVRA) (SVRA) $1.68
G1 Therapeutics Inc (GTHX) (GTHX) $13.10
Soligenix Inc (SNGX) (SNGX) $0.87
Verona Pharma Plc ADR (VRNA) (VRNA) $12.48
Pliant Therapeutics Inc (PLRX) (PLRX) $21.71
Axsome Thera (AXSM) (AXSM) $47.37
Concert Pharmaceutic (CNCE) (CNCE) $6.92
Satsuma Pharmaceuticals Inc (STSA) (STSA) $5.88